Literature DB >> 9507942

Desensitization and resensitization of norepinephrine release in the rat hippocampus with repeated nicotine administration.

Y Fu1, S G Matta, J D Valentine, B M Sharp.   

Abstract

Desensitization of norepinephrine release was investigated with repeated intravenous (i.v.) infusions of nicotine and in vivo microdialysis of the hippocampus. At 100 min intervals, rats received three infusions of one of the following doses of nicotine: 0.045, 0.09 or 0.135 mg/kg. Doses of 0.09 mg/kg or higher increased norepinephrine release (F= 2.41, P < 0.05). However, the norepinephrine response to the second or third infusion was significantly reduced, compared to the first. The extent of desensitization and rate of resensitization was investigated further by administering consecutive infusions of nicotine (0.135 mg/kg) 40, 60, 100 or 200 min apart. Less norepinephrine was released after a second nicotine infusion given 40 to 100 min later, but this was not reduced further by a third infusion. Norepinephrine release was unchanged with a 200 min inter-infusion interval. Therefore, in the hippocampus, maximal desensitization of nicotine-stimulated norepinephrine release occurs as early as 40 min and persists for at least 100 min; thereafter, resensitization becomes the dominant process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507942     DOI: 10.1016/s0304-3940(98)00018-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning.

Authors:  Jennifer A Davis; Thomas J Gould
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

Review 2.  Regulation of feeding-associated peptides and receptors by nicotine.

Authors:  M D Li; S L Parker; J K Kane
Journal:  Mol Neurobiol       Date:  2000 Aug-Dec       Impact factor: 5.590

3.  Norepinephrine secretion in the hypothalamic paraventricular nucleus of rats during unlimited access to self-administered nicotine: An in vivo microdialysis study.

Authors:  Y Fu; S G Matta; V G Brower; B M Sharp
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

4.  Tobacco smoking and the ADRA2A C-1291G polymorphism.

Authors:  A P Prestes; F Z C Marques; M H Hutz; T Roman; C H D Bau
Journal:  J Neural Transm (Vienna)       Date:  2007-07-06       Impact factor: 3.575

Review 5.  Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Authors:  Steven J Simmons; Thomas J Gould
Journal:  J Clin Pharm Ther       Date:  2014-05-14       Impact factor: 2.512

6.  Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning.

Authors:  George S Portugal; Thomas J Gould
Journal:  Pharmacol Biochem Behav       Date:  2007-08-23       Impact factor: 3.533

Review 7.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

8.  Biological basis of tobacco addiction: Implications for smoking-cessation treatment.

Authors:  R C Jiloha
Journal:  Indian J Psychiatry       Date:  2010-10       Impact factor: 1.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.